Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods
- PMID: 6734701
- DOI: 10.1007/BF00548773
Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods
Abstract
The steady state pharmacokinetics of trimethoprim was determined after 300 mg orally once daily to 6 healthy volunteers for 9 days. The microbiological assay of plasma level was unreliable at trimethoprim concentrations greater than 4 micrograms/ml, so results from an HPLC-assay are given. Steady state was present after 3 days. The plasma concentration peaked 1 to 4 h (mean 2.0 h) after the dose at a mean of 6.0 micrograms/ml (range 3.1-9.5 micrograms/ml); the minimum value was 1.5 micrograms/ml (range 0.6-2.9 micrograms/ml). The mean AUCss was 77 micrograms/ml X h and the mean plasma clearances was 67 and 74 ml/min on Days 8 and 9. Renal clearance was about 60% of the plasma clearance. The average plasma half life was 10.6 h (range 8.7-15.3 h). Thus, there was considerable interindividual variation in all pharmacokinetic parameters. 72 h after the last dose trimethoprim was detectable in plasma in only 1 of the 6 subjects. The minimum urinary concentration of trimethoprim during treatment was always well above (range 22 to 220 micrograms/ml) the MIC values for most urinary tract pathogens. Therefore, a daily dose of 300 mg trimethoprim results in a therapeutic concentration in urine at steady state that lasts throughout the dosing interval and in most subjects probably lasts also for a further 24 h. Trimethoprim administration raised mean serum creatinine from 67 to 97 mumol/l, probably due to competitive inhibition of the tubular secretion of creatinine.
Similar articles
-
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.Int J Clin Pharmacol Ther. 2002 May;40(5):198-206. doi: 10.5414/cpp40198. Int J Clin Pharmacol Ther. 2002. PMID: 12051571 Clinical Trial.
-
Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.Antimicrob Agents Chemother. 2004 Sep;48(9):3508-15. doi: 10.1128/AAC.48.9.3508-3515.2004. Antimicrob Agents Chemother. 2004. PMID: 15328118 Free PMC article. Clinical Trial.
-
Pharmacokinetics of trimethoprim given in single daily doses for three days.Scand J Infect Dis. 1982;14(2):143-5. doi: 10.3109/inf.1982.14.issue-2.14. Scand J Infect Dis. 1982. PMID: 7100826
-
Pharmacokinetics of co-trimazine (sulphadiazine plus trimethoprim) in geriatric patients.Chemotherapy. 1986;32(6):478-85. doi: 10.1159/000238456. Chemotherapy. 1986. PMID: 3802953
-
Pharmacokinetics of brodimoprim.J Chemother. 1993 Dec;5(6):475-9. J Chemother. 1993. PMID: 8195840
Cited by
-
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.Eur J Clin Pharmacol. 2013 Jun;69(6):1311-20. doi: 10.1007/s00228-012-1467-3. Epub 2013 Jan 11. Eur J Clin Pharmacol. 2013. PMID: 23307233
-
Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0146821. doi: 10.1128/AAC.01468-21. Epub 2021 Sep 27. Antimicrob Agents Chemother. 2021. PMID: 34570646 Free PMC article.
-
The effect of antibiotic selection on collateral effects and evolvability of uropathogenic Escherichia coli.NPJ Antimicrob Resist. 2024;2(1):19. doi: 10.1038/s44259-024-00037-4. Epub 2024 Jul 17. NPJ Antimicrob Resist. 2024. PMID: 39036800 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources